Author/Authors :
Zareei, L Immunology Research Center - Tabriz University of Medical Sciences, Tabriz, Iran , Divband, B Department of Inorganic Chemistry - Faculty of Chemistry - University of Tabriz, Tabriz, Iran , Mesbahi, A Department of Medical Physics - Tabriz University of Medical Sciences, Tabriz, Iran , Khatamian, M Department of Inorganic Chemistry - Faculty of Chemistry - University of Tabriz, Tabriz, Iran , Kiani, A Department of MRI - Tabriz University of Medical Sciences, Tabriz, Iran , Gharehaghaji, N Department of Radiology - School of Paramedicine - Tabriz University of Medical Sciences, Tabriz, Iran
Abstract :
Background: Magnetic resonance imaging (MRI) contrast agents have an
important role to differentiate healthy and diseased tissues. Access and design new
contrast agents for the optimal use of MRI are necessary. This study aims to evaluate
iron oxide–4A nanocomposite ability to act as a magnetic resonance imaging contrast
agent.
Material and Methods: Iron oxide–4A nanocomposite (F4A) was synthesized.
MTT assay was used to consider the nanocomposite safety for cell culture. The
T1 and T2 relaxation times were measured using a 1.5 Tesla clinical MRI scanner.
Then the corresponding relaxivities were determined.
Results: The average particle diameter of the nanocomposite was 50 to 100 nm
based on scanning electron microscope (SEM) image. A linear relationship between
relaxation rates and the Fe concentration of the nanocomposite was obtained. The T1
and T2 relaxivities of the nanocomposite were calculated 5.413 and 1092.1 mM-1.s-1,
respectively which led to the T2/T1 relaxivity ratio of 201.75.
Conclusion: The high T2/T1 relaxivity ratio of the iron oxide–4A nanocomposite
confirms it’s potential to act as a T2 contrast agent.
Keywords :
Nanocomposite , Iron Oxide , Relaxivity , Contrast Agent , Magnetic Resonance Imaging
